Leukemia, Myelodysplasia, Transplantation
News
Drug can alleviate transfusion dependence in non-del-5q MDS
Photo courtesy of Celgene WASHINGTON, DC—Results of a phase 3 trial support the use of lenalidomide in patients with lower-risk myelodysplastic...
News
Inhibitor gets breakthrough designation for CLL
Though a safety issue previously slowed development of the BCL-2 inhibitor venetoclax (ABT-199), the drug is now moving through the pipeline. The...
Conference Coverage
Agent preferentially targets FLT3-ITD AML
PHILADELPHIA—Preclinical research suggests a novel agent has preferential activity in acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3...
News
Reversing glucocorticoid resistance in ALL
Photo courtesy of St.
News
Inhibitor improves OS in poor-prognosis MDS
WASHINGTON, DC—A small-molecule inhibitor can improve overall survival (OS) in certain patients with previously treated myelodysplastic syndromes...
News
Drug shows promise for lower-risk MDS
WASHINGTON, DC—An investigational drug can increase hemoglobin levels and eliminate transfusion dependence in patients with lower-risk...
News
Targeting receptors to better treat AML
Photo courtesy of UT Southwestern Medical Center Preclinical research suggests that certain receptors containing the immunoreceptor tyrosine-...
Conference Coverage
Susceptibility to 2nd cancers in WM/LPL survivors
PHILADELPHIA—A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM...
Conference Coverage
MKIs can overcome resistance in CML
PHILADELPHIA—Two multikinase inhibitors (MKIs) can treat chronic myeloid leukemia (CML) that is resistant to other inhibitors, according to...
News
Inotuzumab ozogamicin study reaches primary endpoint for ALL
News
Study sheds new light on decitabine
Image by Christoph Bock A new study helps explain how the anticancer drug decitabine reverses cell damage and has revealed a potential biomarker...